MedTrace Logo

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

NCT01292252 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-05-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of 12 weeks of daily treatment with teriparatide on spine fusion in adult patients who are undergoing multi-level posterolateral spine fusion surgery for degenerative conditions of the lumbar spine.

Conditions

  • Lumbar Spondylosis
  • Lumbar Spondylolisthesis
  • Adult Degenerative Lumbar Scoliosis

Interventions

BIOLOGICAL

teriparatide

Teriparatide 20 ug subcutaneous injection daily for 12 weeks

BIOLOGICAL

Placebo

Saline solution

Sponsors & Collaborators

Principal Investigators

  • Shane Burch, MD · University of California, San Francisco

  • Carmen Li · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-12-31
Completion
2016-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01292252 on ClinicalTrials.gov